Second line treatment for relapsed chronic lymphocytic leukemia


Published: June 16, 2009
Abstract Views: 162
PDF: 1341
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

In spite of the remarkable therapeutic achievements obtained with purine analogues and monoclonal antibodies, chronic lymphatic leukaemia (CLL) has still to be considered an incurable disease. Indeed, in the vast majority of patients, the natural history of the disease is characterized by multiple relapses and by multiple remissions, induced by the potential treatments available.

Supporting Agencies


Rossi, G. (2009). Second line treatment for relapsed chronic lymphocytic leukemia. Hematology Meeting Reports (formerly Haematologica Reports), 1(7). https://doi.org/10.4081/hmr.v1i7.630

Downloads

Citations